Pharmaceutical

Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision

Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.

Jul 21, 2023 - 20:00
Cidara to continue its CD388 influenza programme despite Janssen’s contrary decision
Janssen has plans to discontinue the CD388 influenza programme as part of pipeline prioritisation, but Cidara plans to continue development.
Read the original article

Tags:

Previous Article

Idorsia sells off its Asia Pacific operations to raise funds

Next Article

Controlling the pharma machine: EMA conveys thoughts on AI use in industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi invests $1.4bn in insulin production in Germany

Sanofi invests $1.4bn in insulin production in Germany

Aug 3, 2024

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT+: An exit interview with Bristol Myers Squibb CEO ...

Oct 30, 2023

Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19

Invivyd receives FDA IND clearance for VYD222 to preven...

Apr 26, 2023